NYSE:ZTS

Zoetis - ZTS Stock Forecast, Price & News

$150.85

+2.56 (+1.73%)

(As of 10/3/2022 11:22 AM ET)

Add

Compare

Today's Range: $148.42
▼
$151.63
50-Day Range: $148.29
▼
$182.55
52-Week Range: $147.77
▼
$249.27

Volume: 16,998 shs
Average Volume: 2.13 million shs
Market Capitalization: $70.62 billion

P/E Ratio: 34.21
Dividend Yield: 0.88%
Price Target: $224.00

Zoetis MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.86 Rating Score
Upside/Downside: 51.1% Upside
$224.00 Price Target
Short Interest: Healthy
0.90% of Float Sold Short
Dividend Strength: Moderate
Based on Four Factors
Sustainability: -4.66
Upright™ Environmental Score
News Sentiment: 0.28
Based on 12 Articles This Week
Insider Trading: Selling Shares
$2.19 M Sold Last Quarter
Proj. Earnings Growth: 12.63%
From $4.99 to $5.62 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.61 out of 5 stars

Medical Sector

133rd out of 1,093 stocks

Pharmaceutical Preparations Industry

47th out of 548 stocks

3.4

Analyst's Opinion

Consensus Rating
Zoetis has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $224.00, Zoetis has a forecasted upside of 51.1% from its current price of $148.29.
Amount of Analyst Coverage
Zoetis has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.90% of the float of Zoetis has been sold short.
Short Interest Ratio / Days to Cover
Zoetis has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Zoetis has recently increased by 13.21%, indicating that investor sentiment is decreasing significantly.

2.5

Dividend Strength

Dividend Yield
Zoetis has a dividend yield of 0.88%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Zoetis has been increasing its dividend for 8 years.
Dividend Coverage
The dividend payout ratio of Zoetis is 29.48%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Zoetis will have a dividend payout ratio of 23.13% next year. This indicates that Zoetis will be able to sustain or increase its dividend.

0.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Zoetis has received a -79.93% net impact score from Upright. The largest negative impact of Zoetis in category "GHG emissions" seems to be driven mostly by its "Cattle antibiotics", "Cattle vaccines", "Vaccines for pet animals", "Antibiotics for pet animals", and "Cattle dewormers" products. See details.
Environmental Sustainability
The Environmental Impact score for Zoetis is -4.66.

2.4

News and Social Media Coverage

News Sentiment
Zoetis has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Zoetis this week, compared to 6 articles on an average week.
Search Interest
Only 14 people have searched for ZTS on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.
MarketBeat Follows
10 people have added Zoetis to their MarketBeat watchlist in the last 30 days. This is an increase of 43% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Zoetis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,190,623.00 in company stock.
Percentage Held by Insiders
Only 0.12% of the stock of Zoetis is held by insiders.
Percentage Held by Institutions
91.05% of the stock of Zoetis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Zoetis are expected to grow by 12.63% in the coming year, from $4.99 to $5.62 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Zoetis is 33.63, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 109.08.
Price to Earnings Ratio vs. Sector
The P/E ratio of Zoetis is 33.63, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 72.56.
Price to Earnings Growth Ratio
Zoetis has a PEG Ratio of 2.59. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Zoetis has a P/B Ratio of 15.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Zoetis (NYSE:ZTS) Stock

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Receive ZTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.

ZTS Stock News Headlines

October 2, 2022 | finance.yahoo.com

Insiders at Zoetis Inc. (NYSE:ZTS) sold US$4.0m worth of stock, possibly indicating weakness in the future

October 1, 2022 | americanbankingnews.com

Zoetis (NYSE:ZTS) Stock Rating Lowered by StockNews.com

October 3, 2022 | Investing Trends (Ad)

Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium

The soaring demand for lithium is driven by worldwide demand for electric vehicles (EVs). Lithium is ideal for electric cars. It's lightweight, stores lots of energy and is rechargeable. Sales of EVs are expected to increase 10-fold by 2030 and estimates are that 1 in 2 cars sold will be electric by 2040.

September 30, 2022 | businesswire.com

Zoetis Announces the Completion of its Acquisition of Jurox, a Leading Provider of Livestock and Companion Animal Products - Business Wire

September 30, 2022 | finance.yahoo.com

Zoetis Announces the Completion of its Acquisition of Jurox, a Leading Provider of Livestock and Companion Animal Products

September 29, 2022 | finance.yahoo.com

Zoetis to Host Webcast and Conference Call on Third Quarter 2022 Financial Results

September 29, 2022 | americanbankingnews.com

Zoetis (NYSE:ZTS) Sets New 1-Year Low at $147.82

September 28, 2022 | finance.yahoo.com

Here's Why Zoetis (NYSE:ZTS) Has Caught The Eye Of Investors

October 3, 2022 | Investing Trends (Ad)

Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium

September 27, 2022 | finance.yahoo.com

Seen Through Horses Campaign Presented by Zoetis Garners Celebrity and Influencer Support - Yahoo Finance

September 27, 2022 | globenewswire.com

Seen Through Horses Campaign Presented by Zoetis Garners Celebrity and Influencer Support - GlobeNewswire

September 24, 2022 | fool.com

2 Stocks to Buy Near Their 52-Week Lows - The Motley Fool

September 24, 2022 | nasdaq.com

2 Stocks to Buy Near Their 52-Week Lows - Nasdaq

September 24, 2022 | finance.yahoo.com

The Price Is Right For Zoetis Inc. (NYSE:ZTS)

September 21, 2022 | fortune.com

Zoetis CEO on equalizing the work experience for in-office and remote employees - Fortune

September 20, 2022 | finance.yahoo.com

Boasting A 46% Return On Equity, Is Zoetis Inc. (NYSE:ZTS) A Top Quality Stock? - Yahoo Finance

September 20, 2022 | businesswire.com

Zoetis Named a “100 Best Company” and a “Best Company for Dads” by Seramount - Business Wire

September 20, 2022 | fortune.com

Why the leadership style Zoetis CEO Kristin Peck adopted in the pandemic still resonates with her millennial workforce today - Fortune

September 20, 2022 | finance.yahoo.com

Boasting A 46% Return On Equity, Is Zoetis Inc. (NYSE:ZTS) A Top Quality Stock?

September 15, 2022 | seekingalpha.com

Zoetis cleared to acquire Jurox in Australia subject to divestiture (NYSE:ZTS) - Seeking Alpha

September 11, 2022 | finance.yahoo.com

Zoetis to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference - Yahoo Finance

September 11, 2022 | nasdaq.com

Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet? - Nasdaq

September 10, 2022 | wsj.com

The CEO Who Helped Animals Survive Covid-19 - The Wall Street Journal

September 9, 2022 | benzinga.com

Zoetis (NYSE:ZTS) – Zoetis to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference - Benzinga

September 9, 2022 | finance.yahoo.com

Zoetis to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

September 5, 2022 | finance.yahoo.com

TAK or ZTS: Which Is the Better Value Stock Right Now?

September 5, 2022 | seekingalpha.com

Zoetis acquires Scottish animal health digital tech business (NYSE:ZTS) - Seeking Alpha

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ZTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.

ZTS Company Calendar

Ex-Dividend for 9/1 Dividend: 7/20/2022
Last Earnings: 8/04/2022
Dividend Payable: 9/01/2022
Today: 10/03/2022
Next Earnings (Confirmed): 11/03/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NYSE:ZTS
CUSIP: 98978V10
CIK: 1555280
Web: www.zoetis.com
Phone: (973) 822-7000
Fax: 302-655-5049
Employees: 12,100
Year Founded: 2012

Price Target and Rating

Average Stock Price Forecast: $224.00
High Stock Price Forecast: $264.00
Low Stock Price Forecast: $202.00
Forecasted Upside/Downside: +48.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.86
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): $4.41
Trailing P/E Ratio: 34.21
Forward P/E Ratio: 30.23
P/E Growth: 2.59
Net Income: $2.04 billion
Net Margins: 26.14%
Pretax Margin: 32.04%
Return on Equity: 49.03%
Return on Assets: 16.39%

Debt

Debt-to-Equity Ratio: 1.14
Current Ratio: 2.18
Quick Ratio: 1.46

Sales & Book Value

Annual Sales: $7.78 billion
Price / Sales: 9.08
Cash Flow: $5.78 per share
Price / Cash Flow: 26.10
Book Value: $9.60 per share
Price / Book: 15.71

Miscellaneous

Outstanding Shares: 468,139,000
Free Float: 467,577,000
Market Cap: $70.62 billion
Optionable: Optionable
Beta: 0.76

Social Links

Key Executives

Ms. Kristin C. Peck (Age 51)
CEO & Director
Comp: $3.86M

Mr. Glenn C. David (Age 50)
Exec. VP and Group Pres of International Operations, Aquaculture, BioDevices & Pet Insurance
Comp: $1.9M

Mr. Wetteny N. Joseph (Age 50)
Exec. VP & CFO
Comp: $2.91M

Ms. Heidi C. Chen (Age 55)
Exec. VP, Gen. Counsel, Corp. Sec. & Bus. Lead of Human Health Diagnostics
Comp: $1.39M

Ms. Roxanne Lagano (Age 57)
Exec. VP and Chief HR Officer & Global Operations

Ms. Wafaa Mamilli (Age 55)
Exec. VP and Chief Information & Digital Officer

Mr. Steven Frank
VP of Investor Relations

Mr. William Price
VP & Chief Communications Officer

Mr. Timothy J. Bettington (Age 48)
Exec. VP and Pres of U.S. Operations & Global Customer Experience

Mr. Abhay U. Nayak (Age 34)
Exec. VP and Head of Strategy, Accelerated Growth Bus.es & Commercial Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ZTS Stock - Frequently Asked Questions

Should I buy or sell Zoetis stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ZTS shares.
View ZTS analyst ratings or view top-rated stocks.
What is Zoetis' stock price forecast for 2022?: 7 analysts have issued 1 year price objectives for Zoetis' stock. Their ZTS share price forecasts range from $202.00 to $264.00. On average, they predict the company's stock price to reach $224.00 in the next year. This suggests a possible upside of 48.5% from the stock's current price.
View analysts price targets for ZTS or view top-rated stocks among Wall Street analysts.
How have ZTS shares performed in 2022?: Zoetis' stock was trading at $244.03 at the beginning of the year. Since then, ZTS shares have decreased by 38.2% and is now trading at $150.85.
View the best growth stocks for 2022 here.
When is Zoetis' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our ZTS earnings forecast.
How can I listen to Zoetis' earnings call?: Zoetis will be holding an earnings conference call on Thursday, November 3rd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.
How were Zoetis' earnings last quarter?: Zoetis Inc. (NYSE:ZTS) issued its quarterly earnings results on Thursday, August, 4th. The company reported $1.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.22 by $0.02. The company had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.03 billion. Zoetis had a trailing twelve-month return on equity of 49.03% and a net margin of 26.14%. Zoetis's revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.19 EPS.
Read the conference call transcript.
How often does Zoetis pay dividends? What is the dividend yield for Zoetis?: Zoetis announced a quarterly dividend on Thursday, May 19th. Investors of record on Thursday, July 21st will be paid a dividend of $0.325 per share on Thursday, September 1st. This represents a $1.30 annualized dividend and a dividend yield of 0.86%. The ex-dividend date is Wednesday, July 20th.
Read our dividend analysis for ZTS.
Is Zoetis a good dividend stock?: Zoetis (NYSE:ZTS) pays an annual dividend of $1.30 per share and currently has a dividend yield of 0.88%. The company has been increasing its dividend for 8 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 29.48%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ZTS will have a dividend payout ratio of 23.13% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ZTS.

What guidance has Zoetis issued on next quarter's earnings?: Zoetis updated its FY 2022 earnings guidance on Thursday, August, 11th. The company provided EPS guidance of $4.97-$5.05 for the period. The company issued revenue guidance of $8.22 billion-$8.32 billion, compared to the consensus revenue estimate of $8.29 billion.
What is Kristin Peck's approval rating as Zoetis' CEO?: 50 employees have rated Zoetis Chief Executive Officer Kristin Peck on Glassdoor.com. Kristin Peck has an approval rating of 82% among the company's employees. 70.0% of employees surveyed would recommend working at Zoetis to a friend.
What other stocks do shareholders of Zoetis own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Hawkins (HWKN), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Micron Technology (MU), Accenture (ACN) and Transocean (RIG).
What is Zoetis' stock symbol?: Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."
How do I buy shares of Zoetis?: Shares of ZTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Zoetis' stock price today?: One share of ZTS stock can currently be purchased for approximately $150.85.
How much money does Zoetis make?: Zoetis (NYSE:ZTS) has a market capitalization of $70.62 billion and generates $7.78 billion in revenue each year. The company earns $2.04 billion in net income (profit) each year or $4.41 on an earnings per share basis.
How many employees does Zoetis have?: The company employs 12,100 workers across the globe.
Does Zoetis have any subsidiaries?: The following companies are subsidiares of Zoetis: Abaxis, Abaxis Asia Holding Limited, Abaxis Europe GmbH, Abaxis Holding GmbH, Abaxis Inc., Abaxis South East Europe d. o.o., Abaxis UK Limited, Alpharma (Bermuda) LLC, Alpharma (Luxembourg) S.A.R.L. y Compania Limitada, Alpharma (Luxembourg) S.àr.l., Alpharma Animal Health (Hong Kong) Co. Limited, Alpharma Animal Health Company, Alpharma Euro Holdings LLC, Alpharma Holdings (Barbados) SRL, Alpharma LLC, Alpharma do Brasil Ltda., Bovigen, Continental Farmaceutica SPRL, Cross Vetpharm Group Limited, Embrex LLC, Ethos Diagnostic Science, Jilin Zoetis Guoyuan Animal Health Co. Ltd., Mikjan Corporation, NVIP Pty Ltd, Nexvet, Nexvet Australia Pty Ltd, Nordic Fish Tech AB, PAH 7V6 Holding Limited, PAH CHHK Holding B.V., PAH India Holdco LLC, PAH India Holding 1 B.V., PAH Netherlands 2 B.V., PAH Oceania B.V., PAH Spain S.L., PHARMAQ, PHARMAQ LTD, PT Zoetis Animalhealth Indonesia, Performance Livestock Analytics, Pharmaq AS Chile Limitada, Pharmaq AS Service SpA, Pharmaq AS Technika SpA, Pharmaq Analytiq AS, Pharmaq CA Panama Inc., Pharmaq Fishteq AS, Pharmaq Holding AS, Pharmaq Settvac AS, Pharmaq Spain Aqua SL, Pharmaq Veterinar Ecza Deposu ve su Urunleri Ticaret Ltd Ski, Pharmaq Vietnam Company Limited, Phoenix Central Laboratory for Veterinarians Inc., Platinum Performance, Platinum Performance Inc., Platinum Performance Nutrition Inc., Pumpkin Holdings Inc., Pumpkin Insurance Services Inc., Scandinavian Micro Biodevices, Smartbow GmbH, Smartbow RUS OOO, Synbiotics LLC, ZNLabs LLC, ZOETISECUADOR Cia. Ltda., Zoetis (Thailand) Limited, Zoetis Argentina S.R.L., Zoetis Australia Pty Ltd, Zoetis Australia Research & Manufacturing Pty Ltd, Zoetis B.V., Zoetis Belgium S.A., Zoetis Biopharmaceutical Co. Ltd, Zoetis Broomhill IP Limited, Zoetis Broomhill Property Limited, Zoetis C.A., Zoetis Canada Inc., Zoetis Colombia S.A.S., Zoetis Costa Rica S.R.L., Zoetis Denmark Aps, Zoetis Deutschland GmbH, Zoetis Egypt Import LLC, Zoetis Egypt LLC, Zoetis Egypt Pharmaceuticals LLC, Zoetis Egypt Trading LLC, Zoetis Enterprise Management (Shanghai) Co. Ltd., Zoetis Finland Oy, Zoetis France, Zoetis Hayvan Sagligi Ltd. Sti., Zoetis Hellas S.A., Zoetis Holdings LLC, Zoetis Hungary Kft., Zoetis India Limited, Zoetis Indústria de Produtos Veterinários Ltda., Zoetis International Holdings B.V., Zoetis International Services, Zoetis Israël Holding B.V., Zoetis Italia S.r.l., Zoetis Japan K.K., Zoetis Korea Ltd., Zoetis LLC, Zoetis Lab Holdings LLC, Zoetis Luxembourg Holding S.à r.l., Zoetis Malaysia Sdn. Bhd., Zoetis Manufacturing & Research Spain S.L., Zoetis Manufacturing Italia S.R.L., Zoetis Medolla Manufacturing S.R.L., Zoetis Mexico S. de R.L. de C.V., Zoetis Netherlands 1 B.V., Zoetis Netherlands 3 B.V., Zoetis Netherlands 4 B.V., Zoetis Netherlands 5 B.V., Zoetis New Zealand Limited, Zoetis OOO, Zoetis Overseas Holding B.V., Zoetis Overseas Services Inc., Zoetis Panama S. de R.L., Zoetis Pharmaceutical Research Private Limited, Zoetis Philippines Inc., Zoetis Polska sp. z o.o, Zoetis Portugal Lda., Zoetis Products Inc., Zoetis Romania SRL, Zoetis S.R.L., Zoetis Salud Animal de Bolivia S.A., Zoetis Schweiz GmbH, Zoetis Services LLC, Zoetis Singapore Pte. Ltd., Zoetis South Africa (Pty) Ltd., Zoetis Spain S.L., Zoetis Suzhou Manufacturing Co. Ltd., Zoetis Taiwan Limited, Zoetis Treasury Center BVBA, Zoetis UK Limited, Zoetis US LLC, Zoetis Ukraine LLC, Zoetis Vietnam Limited Liability Company, Zoetis WLC LLC, Zoetis Weesp B.V., Zoetis Yantai Manufacturing Co. Ltd., Zoetis de Chile S.A., Zoetis de Uruguay S.R.L., Zoetis Österreich GmbH, and Zoetis Česká republika s.r.o..
Read More
How can I contact Zoetis?: Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The official website for the company is www.zoetis.com. The company can be reached via phone at (973) 822-7000, via email at steve.frank@zoetis.com, or via fax at 302-655-5049.

This page (NYSE:ZTS) was last updated on 10/3/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Zoetis - ZTS Stock Forecast, Price & News

Zoetis MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows